TARO-MEROPENEM 1 G
MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G · DIN 02421526 · SUN PHARMA CANADA INC
Health Canada status: MARKETED
What is TARO-MEROPENEM?
TARO-MEROPENEM 1 G contains MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02421526, held by SUN PHARMA CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-MEROPENEM used for?
TARO - MEROPENEM (meropenem) is indicated for treatment of the following infections when caused by susceptible strains of the designated micro - organisms: Lower Respiratory Tract, Urinary Tract, Intra - abdominal, Gynecologic, Uncomplicated Skin and Skin Structure, Complicated Skin and Skin Structure, Bacterial Meningitis, and Bacterial Septicemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02421526 |
|---|---|
| Brand name | TARO-MEROPENEM |
| Generic / active ingredient | MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G |
| Manufacturer | SUN PHARMA CANADA INC |
| Strength | 1 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DH02 MEROPENEM |
| AHFS class | 08:12.07.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jun-2021 |
| Original market date | 2021-06-11 00:00:00 |
How is it stored and handled?
null
How is it supplied?
500 mg, 1 g per vial
Is MEROPENEM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DH02 MEROPENEM. 15 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02493349 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462893 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528827 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02536374 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02378795 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528819 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02378787 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02493330 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462885 |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 1 G | POWDER FOR SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02544342 |
Who else supplies MEROPENEM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MEROPENEM appears in 852 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.